Featured Research

from universities, journals, and other organizations

Drug-eluting stent keeps pathway open for people with severe lower extremity disease

Date:
May 15, 2014
Source:
Houston Methodist
Summary:
A new stent has been effective at keeping arteries open in the lower extremities of patients with peripheral artery disease (PAD) for more than four years. PAD is a chronic, progressive circulatory disease in which plaque builds up in the arteries that carry blood to the rest of the body. Over time, the plaque can harden and narrow the arteries, restricting blood flow. This condition affects between 8 and 12 million Americans, even though some do not experience symptoms like pain or cramping in the lower extremities.

Lack of blood flow to the lower extremities can cause severe leg cramps and foot pain in those who suffer from peripheral artery disease (PAD). A new drug-eluting stent is bringing relief to those patients by opening up severely clogged arteries and keeping them open longer. In clinical studies, it cut re-intervention in half.

The Zilver® PTX® by Cook Medical® is a bare metal stent that when deployed expands and opens up clogged arteries. What sets it apart from other stents is the drug Paclitaxel, which coats the stent. This drug is also used in chemotherapy treatments to fight various types of cancers such as breast, ovarian and lung. The stent opens up the arteries and the drug, which soaks up the cells of the arterial wall, prevents the re-narrowing of the arteries over time.

"We've used bare metal stents in the past, but many patients had rapid recurrence of their arterial blockages due to excessive tissue reaction to the presence of the stents," said Dr. Hosam El-Sayed, an endovascular surgeon with Houston Methodist Hospital. "This new stent is the first to combine the mechanical support of a stent and a powerful drug to reduce the risk of future blockages."

PAD is a chronic, progressive circulatory disease in which plaque builds up in the arteries that carry blood to the rest of the body. Over time, the plaque can harden and narrow the arteries, restricting blood flow. This condition affects between 8 and 12 million Americans, even though some do not experience symptoms like pain or cramping in the lower extremities.

A four-year study of 479 patients found a 75 percent patency rate for those with the Zilver® PTX® compared to 58 percent who had the regular bare metal stents.

"This very exciting because these numbers are approaching the results with bypass surgery, which is an effective and long lasting open procedure, but is a much bigger operation with a much longer recovery time," El-Sayed said. "This procedure can be done minimally-invasively and is a great leap forward in the treatment of the lower extremities disease because it offers marked improvement in the results of endovascular treatment of those patients."


Story Source:

The above story is based on materials provided by Houston Methodist. Note: Materials may be edited for content and length.


Cite This Page:

Houston Methodist. "Drug-eluting stent keeps pathway open for people with severe lower extremity disease." ScienceDaily. ScienceDaily, 15 May 2014. <www.sciencedaily.com/releases/2014/05/140515103700.htm>.
Houston Methodist. (2014, May 15). Drug-eluting stent keeps pathway open for people with severe lower extremity disease. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/05/140515103700.htm
Houston Methodist. "Drug-eluting stent keeps pathway open for people with severe lower extremity disease." ScienceDaily. www.sciencedaily.com/releases/2014/05/140515103700.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins